Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Number 7—July 2025

Research

Estimation of Incubation Period for Oropouche Virus Disease among Travel-Associated Cases, 2024–2025

On This Page
Methods
Results
Discussion
Suggested Citation
Figures
Figure 1
Figure 2
Figure 3
Tables
Table 1
Table 2
Downloads
Appendix
RIS [TXT - 2 KB]
Article Metrics
Metric Details
Author affiliation: Author affiliations: Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (S.A.J. Guagliardo, S. Martin, C.V. Gould, R. Sutter, D. Jacobs, J.E. Staples); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (K. O’Laughlin); IRCCS Sacro Cuore Don Calabria Hospital, Verona, Italy (R. Huits, C. Castilletti)

Suggested citation for this article

Abstract

Determining the incubation period of Oropouche virus disease can inform clinical and public health practice. We analyzed data from 97 travel-associated cases identified by the Centers for Disease Control and Prevention (n = 74) or the GeoSentinel Network (n = 13) and 10 cases from published literature. Using log-normal interval-censored survival analysis, we estimated the median incubation period to be 3.2 (95% CI 2.5–3.9) days. Symptoms developed by 1.1 (95% CI 0.6–1.5) days for 5% of patients, 9.7 (95% CI 6.9–12.5) days for 95% of patients, and 15.4 (95% CI 9.6–21.3) days for 99% of patients. The estimated incubation period range of 1–10 days can be used to assess timing and potential source of exposure in patients with Oropouche symptoms. For patients with symptom onset >2 weeks after travel, clinicians and public health responders should consider the possibility of local vectorborne transmission or alternative modes of transmission.

Oropouche virus disease (Oropouche) is caused by infection with Oropouche virus (OROV; genus Orthobunyavirus, Simbu serogroup). In late 2023, a large outbreak of Oropouche originated in the Brazilian Amazon, later expanding into endemic and nonendemic regions in the Americas, and >16,000 cases were reported by the end of 2024 (1). Since 2023, >140 cases have been identified in travelers returning to Europe and North America, predominantly from Cuba (2).

Clinical manifestations of Oropouche are similar to those of other vectorborne diseases, such as dengue, Zika, and chikungunya, and are characterized by acute onset of fever, headache, myalgia, fatigue, chills, and arthralgia (3). Other symptoms can include diarrhea, nausea, vomiting, maculopapular rash, abdominal pain, retroorbital pain, back pain, and photophobia (4). Although most Oropouche cases are mild, severe disease and death have been reported (5). Severe manifestations of illness include hemorrhagic symptoms (e.g., gingival bleeding, melena, and menorrhagia), neurologic symptoms (e.g., meningitis, meningoencephalitis, Guillain-Barré syndrome), and adverse pregnancy outcomes (6–9).

OROV is primarily transmitted to humans through the bites of infected biting midges (Culicoides paraensis) and possibly certain mosquito species, such as Culex quinquefasciatus. Other observed transmission modes have included accidental inoculation via oral and respiratory routes in a laboratory setting (10). Oropouche viral RNA was recently detected in the semen of 2 travelers returning to Europe from Cuba, raising questions about the possibility of sexual transmission, although that mode of transmission has not yet been confirmed (11,12). Congenital transmission is also suspected because of reported maternal infections during pregnancy that resulted in birth defects and laboratory evidence of OROV infection in those infants (9).

The incubation period for Oropouche was previously estimated to range from 3 to 10 days, but that estimate was based on just 2 cases (3,6,10). Having a more precise estimation of the incubation period can help clinicians form a differential diagnosis on the basis of timing of potential exposures and help public health officials distinguish between travel-associated cases and local transmission. We estimated the Oropouche incubation period using data from infected travelers returning to nonendemic areas.

Methods

Data Sources

Figure 1

Flowchart of data sources and 97 cases included in an estimation of incubation period for Oropouche virus disease among travel-associated cases, 2024–2025. The study included patients who developed symptoms and had positive test results for Oropouche in the laboratory database of the CDC Arboviral Diseases Branch (Division of Vector-borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases), through GeoSentinel (https://geosentinel.org), or in reports available on PubMed as of March 15, 2025. We excluded patients without complete travel data. *(6,11,13–15). CDC, Centers for Disease Control and Prevention.

Figure 1. Flowchart of data sources and 97 cases included in an estimation of incubation period for Oropouche virus disease among travel-associated cases, 2024–2025. The study included patients who developed symptoms and...

We used 3 data sources: the laboratory database of OROV testing conducted during 2024–2025 through the Centers for Disease Control and Prevention (CDC) Arboviral Diseases Branch (Division of Vector-borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases); the GeoSentinel Network database (https://geosentinel.org) of patients identified with Oropouche during 2024; and a PubMed search of the literature through March 15, 2025, using the search terms “Oropouche” or “Oropuche” (Figure 1). At CDC, suspected cases were tested by real-time reverse transcription PCR (rRT-PCR) or 90% plaque reduction neutralization test, depending on the timing of specimen collection relative to symptom onset (16). The GeoSentinel Network, a collaboration between CDC and the International Society of Travel Medicine, is a global surveillance system for illnesses affecting international travelers currently comprised of ≈70 clinical sites in 30 countries. Patients identified and tested through the GeoSentinel Network were tested for evidence of OROV infection by rRT-PCR or IgG and IgM serology. For each case-patient, we extracted basic demographic data (age and sex), symptom onset date, travel dates, and whether the patient was hospitalized. Patients self-reported symptom onset date and travel dates. We ensured no overlap among patients identified through those sources by verifying that demographic data and travel dates were unique.

Case Classification and Inclusion Criteria

We included probable and confirmed cases of Oropouche. We defined a probable case as a patient with a known epidemiologic link whose blood or cerebrospinal fluid sample tested positive for OROV-specific IgM or neutralizing antibodies. We defined a confirmed case as a patient with a known epidemiologic link whose sample was OROV-positive by rRT-PCR, had a >4-fold change in neutralizing antibody titers in paired serum samples, or was positive for IgM in blood or cerebrospinal fluid with confirmatory virus-specific neutralizing antibodies. We only included symptomatic patients that had complete information about travel destinations, departure and return dates, and symptom onset date. We considered any of the symptoms included in the suspected case definition (e.g., fever, chills, headache, myalgia, arthralgia, retro-orbital pain, or generalized rash) to denote the onset of symptoms, as self-reported by patients.

Statistical Analysis

Figure 2

Time of exposure relative to symptom onset in an estimation of incubation period for Oropouche virus disease among 97 probable and confirmed travel-associated cases, 2024–2025. Each horizontal line corresponds to an individual patient’s exposure time. The vertical black line represents symptom onset. The horizontal lines represent the exposure durations before (dark blue) and after (light blue) symptom onset. Observations are ordered by duration of travel, and long travel durations are truncated from the graph for ease of interpretation. The black triangle represents the median incubation period for probable and confirmed cases; the white triangle represents the 95th quantile.

Figure 2. Time of exposure relative to symptom onset in an estimation of incubation period for Oropouche virus disease among 97 probable and confirmed travel-associated cases, 2024–2025. Each horizontal line corresponds to...

We conducted descriptive statistics on patient demographics (age and sex) and travel characteristics (travel duration and location). We used parametric interval-censored survival modeling to estimate the incubation period distribution (17,18). We determined the exposure period by using the dates of travel relative to the timing of illness onset. Specifically, for patients whose symptoms developed after travel, we considered the exposure period to be the duration of travel, and for patients whose symptoms developed during travel, we considered the exposure period to be from the beginning of travel through the illness onset date (Figure 2) (17,18).

We fitted probability distributions (Weibull, log-normal, and Gamma) to the data by using the dic.fit function in the coarseDataTools package in R (The R Project for Statistical Computing, https://www.r-project.org) and selected the best-fitting distribution using the Akaike information criterion (17,18). We calculated cumulative distribution functions and associated 95% CIs, along with means, medians, and 5th, 95th, and 99th quantiles. We also evaluated whether estimated incubation period varied by age, sex, and hospitalization status by fitting parametric log-normal models for each covariate using the survreg procedure in the survival package in R.

The initial analysis included all patients that met inclusion criteria. To provide a more precise estimate of incubation periods, we also performed an analysis on a subset of patients meeting the case definition for confirmed Oropouche and who had <14 days of travel. Last, we analyzed a subset of cases detected in 2024–2025 to examine if the current viral strain affected the incubation period estimates.

Ethics Considerations

This activity was reviewed by CDC, was deemed not research, and was conducted consistent with applicable federal law and CDC policy (project no. 0900f3eb824f7cc8). Applicable federal laws include 45 C.F.R. part 46.102(l) (2), 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq. A human subjects advisor at CDC’s National Center for Emerging and Zoonotic Infectious Diseases reviewed the GeoSentinel surveillance data collection protocol and classified it as public health surveillance and not human subjects research (project no. 0900f3eb81bc3a03). Additional ethics clearance was obtained by GeoSentinel sites, as required by their respective institutions.

Results

In total, 97 cases met the inclusion criteria, consisting of 74 cases identified on the basis of testing conducted at CDC, 13 reported to GeoSentinel, and 10 identified in the peer-reviewed literature (Figure 1). The symptom onset dates ranged from October 2010 to January 2025, and 98% (n = 95) of cases occurred during 2024–2025.

Most (96%, n = 93) patients were adults >19 years of age; 54 (56%) were female and 43 (44.3%) were male (Table 1). More than half (57%, n = 55) of patients had initial symptoms develop during travel, and the median exposure period was 7 days (interquartile range [IQR] 6.0–14.0 days; range 2–135 days) (Figure 2). The most common travel location was Cuba, as reported by 97% (n = 94) of patients. The demographic characteristics of the confirmed and probable cases compared with confirmed cases with <14 days of travel were similar (Table 1). Compared with cases identified through GeoSentinel and published literature, patients whose samples were tested at CDC were older (median age 51 years for cases tested at CDC vs. 30 years for cases identified elsewhere; p<0.0001), less likely to have been hospitalized (16% vs. 40%; p = 0.041), and had shorter exposure periods (median 7 days vs. 14 days; p<0.0001) (Appendix Table 1).

Figure 3

Estimated cumulative distribution of incubation period for Oropouche virus disease among 97 probable and confirmed travel-associated cases, 2024–2025. Solid blue line represents the estimated log-normal cumulative distribution function; shaded area represents 95% CI. Dashed lines correspond to the 50th and 99th quantiles, in addition to the proportion of patients that experienced symptoms within 1 week (88th quantile). The solid horizontal lines at bottom represent the 95% CIs for the quantiles.

Figure 3. Estimated cumulative distribution of incubation period for Oropouche virus disease among 97 probable and confirmed travel-associated cases, 2024–2025. Solid blue line represents the estimated log-normal cumulative distribution function; shaded area...

The log-normal distribution was the best fit for all case sets (Appendix Table 2). For probable and confirmed cases (n = 97), the estimated median incubation period was 3.2 (95% CI 2.5–3.9) days (Table 2). We estimated symptoms developed within 1.1 (95% CI 0.6–1.5) days for 5% of patients and within 9.7 (95% CI 6.9–12.5) days for 95% of patients. We estimated that most (88%) patients’ symptoms developed within 7 days (Figure 3). Our estimates show that almost all (99%) patients had symptoms develop by 15.4 (95% CI 9.6–21.3) days. The estimated median incubation period for confirmed cases only was similar at 3.1 (95% CI 2.1–4.0) days, and 95% of confirmed cases had symptoms develop within 9.3 (95% CI 5.4–13.2) days (Appendix Table 3). Estimated incubation periods did not differ substantially by age, sex, hospitalization status, or when we excluded the 2 cases that occurred before 2024 (Appendix Tables 3, 4).

Discussion

In this analysis of travel-associated Oropouche cases, we estimated the median incubation period to be 3–4 days, with a range of 1 day (5% of cases) to 10 days (95% of cases). We estimated symptoms developed within 3 days of exposure for 50% of patients and within 15 days for 99% of patients.

Globally, most travel-associated Oropouche cases during the 2024 outbreak were among persons returning from Cuba to the United States, and the data used in this analysis reflects that pattern (2,19). Before 2024, OROV transmission was not suspected in Cuba, and the population likely had no immunity. By the end of 2024, Cuba had 24,259 suspected cases, of which 626 were confirmed cases (20), suggesting high levels of transmission and increased likelihood of repetitive exposure among visitors to Cuba. Compared with travelers to other areas, the estimated incubation period might have been shorter for US travelers to Cuba because they traveled to an area with an active outbreak and likely were exposed, potentially repeatedly, soon after arrival. Going forward, additional data from travelers to other geographic areas can be incorporated to improve the representativeness and precision of the estimate of this Oropouche incubation period.

Prior estimates for the range of the incubation period of Oropouche have included 3–8 days, 4–8 days, and 3–10 days (3,21,22). Our estimate of 1–10 days has a wider overall range than prior estimates, noting symptom onset can occur within 1 day of exposure for 5% of patients. The previous lower estimate of 3 days was based on the symptom onset in a laboratory worker who was exposed orally, and the previous upper estimate of 10 days was documented in a traveler from Brazil who returned to a nonendemic area after visiting the Amazon region (6,10). The incubation period of 4–8 days was based on an assessment of historical outbreaks in the Brazilian Amazon in the 1960s and 1970s but could not be determined with precision because the exact timing of exposure was unknown for cases in or near endemic areas (10). However, evidence suggests that the current viral reassortant replicates faster than the prototype strain, possibly impacting incubation period for infections associated with recent outbreaks (23).

In clinical settings, providers should take a thorough history to determine the timing of the patient’s initial symptom onset because relapse of symptoms has been described in up to 70% of Oropouche patients (24). Suspicion for Oropouche should be heightened when a patient has a compatible illness within 10 days of returning from an area with active virus transmission. Clinicians should also consider the patient’s underlying immunocompetence, which has been shown to affect incubation period in other arboviral infections, such as West Nile virus (25). However, no data are available on the effect of immunosuppression on the Oropouche incubation period. For most patients with clinically compatible illness >2 weeks after travel, alternative diagnoses should be considered. If the patient has laboratory evidence of OROV infection, clinicians should evaluate the possibility of local vectorborne transmission or alternative transmission modes.

Although Oropouche is clinically similar to other arboviral diseases, the median incubation period estimated from this analysis (3–4 days; range 1–10 days) is shorter than those for dengue (5–7 days; range 3–10 days), chikungunya (3–7 days; range 1–12 days), and Zika (6–7 days; range 3–14 days) (17,26,27). However, because the estimated ranges of those incubation periods overlap, clinicians should consider potential exposures and other clinical and epidemiologic information when deciding on testing and differential diagnosis.

Knowing the Oropouche incubation period can help direct case investigations and public health response to outbreaks. For example, when OROV infection is confirmed in a traveler >2 weeks after returning to a nonendemic area, public health authorities should consider the possibility of local vectorborne transmission, provided competent vectors are present and seasonality is appropriate, or alternative modes of transmission. Although sexual transmission of OROV has not yet been documented, identification of culturable virus on a day 16 semen sample indicates sexual transmission could occur and should be investigated (11). Accurate incubation periods can also help develop criteria for determining the end of an outbreak. A commonly used criterion is twice the longest estimated incubation period without observing any new cases since the last transmission event (28). On the basis of the upper limit of the extrinsic incubation period in the vector Cu. paraensis midge (8 days) and the upper limit of our estimate of intrinsic incubation (95th quantile of 10 days), a period up to 5 weeks (≈18 days × 2) with no new cases in an area under adequate epidemiologic surveillance could be used to declare the end of an outbreak (29).

The first limitation of this study is that the clinically apparent cases included in this analysis potentially biased our results toward shorter incubation periods compared with cases of mild disease. Second, our estimates were based on data from infected travelers, who might have different underlying demographic and medical characteristics compared with nontravelers. Third, our dataset was relatively small, resulting in estimates with less certainty for the upper end of the log-normal distribution (95th and 99th quantiles). Not unexpectedly, 1 extreme observation in our dataset had an exposure window that ended >15 days (99th quantile) before symptom onset. Unusually long lapses between the end of an exposure period and symptom onset could also be explained by recall bias because travel duration and symptom onset dates were self-reported by patients. Fourth, data for this project were derived from distinct sources, so event data (e.g., symptom onset) might have been collected differently, impacting the precision of our estimates. Finally, we considered exposures to be vectorborne for cases included in the analysis, but patients with alternative exposures might also have been included in the dataset.

In conclusion, our results indicate that 50% of travelers infected with OROV will develop symptoms within 3–4 days of exposure and 99% will develop symptoms within 15 days. Clinicians and public health responders should evaluate the possibility of alternative modes of transmission (e.g., sexual transmission) or local vectorborne transmission for travelers with Oropouche who develop symptoms >2 weeks after travel. Our estimate of the distribution of the Oropouche incubation period will help clinicians and public health officials develop a differential diagnosis based on the timing of travel-related exposures and inform prevention and control measures.

Dr. Guagliardo is an epidemiologist with the Division of Vector-Borne Diseases, , National Center for Emerging and Zoonotic Infectious Diseases, CDC, Fort Collins, Colorado. Her research interests include the applied epidemiology and ecology of emerging and re-emerging vectorborne diseases.

Top

Acknowledgments

We thank Jennifer Lehman for management of clinical laboratory data and CDC staff members and state and local health departments that contributed to the Oropouche Virus Response.

Funding for this project was supported by CDC. GeoSentinel is supported by a cooperative agreement (no. 5U01CK000632-04) between CDC and the International Society of Travel Medicine.

GeoSentinel Network Collaborators: Sami Alcedo, Hilmir Asgeirsson, Anna Barbiero, Ilsa Beig, Emmanuel Bottieau, David Brett-Major, Rosa De Miguel Buckley, Claudia Denkinger, Hedvig Glans, Frederico Gobbi, David Hamer, Michael Libman, Laura Nicolini, Francesca Norman, Jose A. Perez-Molina, Chiara Sepulcri, Theresa Sepulveda, Federica Toscanini, Els van Nood, Jesse Waggoner, and Lorenzo Zammarchi.

Top

References

  1. Pan American Health Organization. Epidemiological update Oropouche in the Americas region, 11 February 2025 [cited 20025 Feb 11]. https://www.paho.org/sites/default/files/2025-02/2025-feb-10-epi-update-oropoucheeng-final_0.pdf
  2. Centers for Disease Control and Prevention. Oropouche in the United States [cited 2025 Apr 29]. https://www.cdc.gov/oropouche/data-maps/current-year-data.html
  3. Guagliardo  SAJ, Connelly  CR, Lyons  S, Martin  SW, Sutter  R, Hughes  HR, et al. Reemergence of Oropouche virus in the Americas and risk for spread in the United States and its territories, 2024. Emerg Infect Dis. 2024;30:2241–9. DOIPubMedGoogle Scholar
  4. Morrison  A, White  JL, Hughes  HR, Guagliardo  SAJ, Velez  JO, Fitzpatrick  KA, et al. Oropouche virus disease among U.S. travelers—United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73:769–73. DOIPubMedGoogle Scholar
  5. Bandeira  AC, Pereira  FM, Leal  A, Santos  SPO, Barbosa  AC, Souza  MSPL, et al. Fatal Oropouche virus infections in nonendemic region, Brazil, 2024. Emerg Infect Dis. 2024;30:2370–4. DOIPubMedGoogle Scholar
  6. Vernal  S, Martini  CCR, da Fonseca  BAL. Oropouche virus-associated aseptic meningoencephalitis, southeastern Brazil. Emerg Infect Dis. 2019;25:380–2. DOIPubMedGoogle Scholar
  7. de Armas Fernández  JR, Peña García  CE, Acosta Herrera  B, Betancourt Plaza  I, Gutiérrez de la Cruz  Y, Resik Aguirre  S, et al. Report of an unusual association of Oropouche Fever with Guillain-Barré syndrome in Cuba, 2024. Eur J Clin Microbiol Infect Dis. 2024;43:2233–7. DOIPubMedGoogle Scholar
  8. Mourãão  MP, Bastos  MS, Gimaqu  JB, Mota  BR, Souza  GS, Grimmer  GHN, et al. Oropouche fever outbreak, Manaus, Brazil, 2007-2008. Emerg Infect Dis. 2009;15:2063–4. DOIPubMedGoogle Scholar
  9. das Neves Martins  FE, Chiang  JO, Nunes  BTD, Ribeiro  BFR, Martins  LC, Casseb  LMN, et al. Newborns with microcephaly in Brazil and potential vertical transmission of Oropouche virus: a case series. Lancet Infect Dis. 2025;25:155–65. DOIPubMedGoogle Scholar
  10. Pinheiro  FP, Travassos da Rosa  AP, Travassos da Rosa  JF, Ishak  R, Freitas  RB, Gomes  ML, et al. Oropouche virus. I. A review of clinical, epidemiological, and ecological findings. Am J Trop Med Hyg. 1981;30:149–60. DOIPubMedGoogle Scholar
  11. Castilletti  C, Huits  R, Mantovani  RP, Accordini  S, Alladio  F, Gobbi  F. Replication-competent Oropouche virus in semen of traveler returning to Italy from Cuba, 2024. Emerg Infect Dis. 2024;30:2684–6. DOIPubMedGoogle Scholar
  12. Iglói  Z, Soochit  W, Munnink  BBO, Anas  AA, von Eije  KJ, van der Linden  A, et al. Oropouche virus genome in semen and other body fluids from traveler. Emerg Infect Dis. 2025;31:205–6. DOIPubMedGoogle Scholar
  13. Barbiero  A, Formica  G, Mantovani  RP, Accordini  S, Gobbi  F, Spinicci  M, et al. Persistent Oropouche virus viremia in two travellers returned to Italy from Cuba, July 2024. J Travel Med. 2025;32:taae148. DOIPubMedGoogle Scholar
  14. Gourjault  C, Pezzi  L, Doudier  B, Minodier  P, Klitting  R, Cano  P, et al. Persistence of Oropouche virus in body fluids among imported cases in France, 2024. Lancet Infect Dis. 2025;25:e64–5. DOIPubMedGoogle Scholar
  15. de Souza Luna  LK, Rodrigues  AH, Santos  RI, Sesti-Costa  R, Criado  MF, Martins  RB, et al. Oropouche virus is detected in peripheral blood leukocytes from patients. J Med Virol. 2017;89:1108–11. DOIPubMedGoogle Scholar
  16. Naveca  FG, Nascimento  VAD, Souza  VC, Nunes  BTD, Rodrigues  DSG, Vasconcelos  PFDC. Multiplexed reverse transcription real-time polymerase chain reaction for simultaneous detection of Mayaro, Oropouche, and Oropouche-like viruses. Mem Inst Oswaldo Cruz. 2017;112:510–3. DOIPubMedGoogle Scholar
  17. Krow-Lucal  ER, Biggerstaff  BJ, Staples  JE. Estimated incubation period for Zika virus disease. Emerg Infect Dis. 2017;23:841–5. DOIPubMedGoogle Scholar
  18. Reich  NG, Lessler  J, Cummings  DA, Brookmeyer  R. Estimating incubation period distributions with coarse data. Stat Med. 2009;28:2769–84. DOIPubMedGoogle Scholar
  19. European Centers for Disease Control and Prevention. Threat assessment brief: Oropouche virus disease cases imported into the European Union [cited 2025 Apr 29]. https://www.ecdc.europa.eu/sites/default/files/documents/TAB-Oropouche-august-2024.pdf
  20. Pan American Health Organization. Countries with cumulative reports of Oropouche cases [in Spanish] [cited 2025 Apr 29]. https://www.paho.org/es/arbo-portal/oropouche
  21. Sakkas  H, Bozidis  P, Franks  A, Papadopoulou  C. Oropouche fever: a review. Viruses. 2018;10:175. DOIPubMedGoogle Scholar
  22. Pinheiro  FP, Travassos da Rosa  APA, Vasconcelos  PF. Oropouche fever. In: Feigin RD, Demmler GJ, Cherry JD, Kaplan SL, editors. Textbook of pediatric infectious diseases, 5th ed. Philadelphia (PA): W.B. Saunders Co; 2004. p. 2418–23.
  23. Scachetti  GC, Forato  J, Claro  IM, Hua  X, Salgado  BB, Vieira  A, et al. Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study. Lancet Infect Dis. 2025;25:166–75. DOIPubMedGoogle Scholar
  24. Azevedo  RS, Nunes  MR, Chiang  JO, Bensabath  G, Vasconcelos  HB, Pinto  AY, et al. Reemergence of Oropouche fever, northern Brazil. Emerg Infect Dis. 2007;13:912–5. DOIPubMedGoogle Scholar
  25. Pealer  LN, Marfin  AA, Petersen  LR, Lanciotti  RS, Page  PL, Stramer  SL, et al.; West Nile Virus Transmission Investigation Team. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med. 2003;349:1236–45. DOIPubMedGoogle Scholar
  26. Chan  M, Johansson  MA. The incubation periods of Dengue viruses. PLoS One. 2012;7:e50972. DOIPubMedGoogle Scholar
  27. Rudolph  KE, Lessler  J, Moloney  RM, Kmush  B, Cummings  DA. Incubation periods of mosquito-borne viral infections: a systematic review. Am J Trop Med Hyg. 2014;90:882–91. DOIPubMedGoogle Scholar
  28. Djaafara  BA, Imai  N, Hamblion  E, Impouma  B, Donnelly  CA, Cori  A. A quantitative framework for defining the end of an infectious disease outbreak: application to Ebola virus disease. Am J Epidemiol. 2021;190:642–51. DOIPubMedGoogle Scholar
  29. Pinheiro  FP, Hoch  AL, Gomes  ML, Roberts  DR. Oropouche virus. IV. Laboratory transmission by Culicoides paraensis. Am J Trop Med Hyg. 1981;30:172–6. DOIPubMedGoogle Scholar

Top

Figures
Tables

Top

Suggested citation for this article: Guagliardo SAJ, Martin S, Gould CV, Sutter R, Jacobs D, O’Laughlin K, et al.; GeoSentinel Network Collaborators. Estimation of incubation period for Oropouche virus disease among travel-associated cases, 2024–2025. Emerg Infect Dis. 2025 Jul [date cited]. https://doi.org/10.3201/eid3107.250468

DOI: 10.3201/eid3107.250468

Original Publication Date: May 01, 2025

1Members are listed at the end of this article.

Table of Contents – Volume 31, Number 7—July 2025

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Sarah Anne J. Guagliardo, Centers for Disease Control and Prevention, 3156 Rampart Rd, Mailstop 4-325, Fort Collins, CO 80521, USA

Send To

10000 character(s) remaining.

Top

Page created: April 30, 2025
Page updated: May 01, 2025
Page reviewed: May 01, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external